NRAS and melanoma: Within this study, the effect of a so far well-characterized antitumor peptide, RDP22 (R-DIM-P-LF11-322) on the highly aggressive melanoma metastasis cell line MUG-Mel2, carrying an NRAS mutation, was investigated.